U. Christopher Missling's Insider Trades & SAST Disclosures
U. Christopher Missling's most recent trade in Anavex Life Sciences Corporation was a trade of 500,000 Common Stock done at an average price of $0.9 . Disclosure was reported to the exchange on March 24, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern U. Christopher Missling.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Anavex Life Sciences Corpo... | Christopher U. Missling | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.92 per share. | 24 Mar 2025 | 500,000 | 1,750,210 (2%) | 0% | 0.9 | 460,000 | Common Stock |
| Anavex Life Sciences Corpo... | Christopher U. Missling | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2025 | 500,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Christopher U. Missling | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.63 per share. | 24 Mar 2025 | 282,497 | 1,467,713 (2%) | 0% | 9.6 | 2,720,446 | Common Stock |
| Anavex Life Sciences Corpo... | Christopher U. Missling | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 166,666 | 166,000 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Christopher U. Missling | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | U. Christopher Missling | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Christopher U. Missling | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2024 | 125,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Christopher U. Missling | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2024 | 73,380 | 0 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Christopher U. Missling | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 5.11 per share. | 28 Mar 2024 | 73,380 | 1,250,210 (2%) | 0% | 5.1 | 374,972 | Common Stock |
| Anavex Life Sciences Corpo... | Christopher U. Missling | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.32 per share. | 28 Mar 2024 | 73,380 | 1,323,590 (2%) | 0% | 1.3 | 96,862 | Common Stock |
| Anavex Life Sciences Corpo... | U. Missling Christopher | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Christopher U. Missling | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Christopher U. Missling | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2021 | 51,620 | 73,380 | - | - | Stock Option (Right to Buy) | |
| Anavex Life Sciences Corpo... | Christopher U. Missling | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.32 per share. | 29 Jun 2021 | 51,620 | 1,069,830 (1%) | 0% | 1.3 | 68,138 | Common Stock |
| Anavex Life Sciences Corpo... | Christopher U. Missling | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 26.00 per share. | 29 Jun 2021 | 51,620 | 1,018,210 (1%) | 0% | 26 | 1,342,120 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges